Category: COVID-19 Developments

September 17, 2023
WCRI Publishes Long COVID Report

The likelihood of long COVID, claims costs, and claim duration all increased with the severity of acute COVID-19.

READ MORE
October 15, 2022
FDA Warns That Certain COVID-19 Variants are Not Neutralized by Evusheld

The only pre-exposure prophylactic for COVID-19 may not provide protection for certain variants.

READ MORE
September 25, 2022
FDA Authorizes Additional Round of COVID-19 Boosters

Moderna and Pfizer boosters have been updated to target the omicron variant.

READ MORE
April 19, 2022
FDA Authorizes Second COVID-19 Booster Dose for Special Populations

Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.

READ MORE
February 19, 2022
FDA Fully Approves Moderna Vaccine & Expands Veklury’s Treatment Range

Drug advancements surrounding the prevention and treatment of COVID-19.

READ MORE
January 15, 2022
Additional Vaccine Candidate Performs Well in Clinical Trials

Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.

READ MORE
December 16, 2021
FDA Authorizes COVID-19 Booster Shots for All Adults

All adults may now receive a booster shot of any COVID-19 vaccine.

READ MORE
November 15, 2021
FDA Authorizes Booster Shots for Moderna and J&J Vaccines

All COVID-19 vaccines now have emergency use authorization for a booster dose.

READ MORE
August 2, 2021
The Early Impact of COVID-19 on Workers’ Comp Claims

Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.

READ MORE
May 10, 2021
FDA Revokes Emergency Use Authorization for Bamlanivimab for COVID-19

Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.

READ MORE
lockenvelopephone-handsetmagnifiermenucross-circle